As Assistant Professor of Oncology at the Department of Pharmacology and Therapeutics, I joined Roswell Park Comprehensive Cancer Center in July of 2019. In addition to leading my independent research program, I serve as the Associate Director for Pharmacokinetics & Pharmacodynamics at the BMPK Shared Resource to handle requests for PK/PD analyses of anticancer drugs.
After obtaining my PharmD degree at Utrecht University in the Netherlands in 2008, I started my PhD research on clinical herb-drug interactions in oncology at the Department of Pharmacoepidemiology and Clinical Pharmacology at Utrecht University in the Netherlands. Under the supervision of Irma Meijerman, PhD, Jan Schellens MD, PhD, and Jos Beijnen, PharmD, PhD, I coordinated several Phase I interaction studies and developed LC-MS/MS assays for quantification of herbal components in human matrices. During my PhD project, I also obtained board certification as a Clinical Pharmacologist issued by the Dutch Society for Clinical Pharmacology and Biopharmacy.
When I completed my PhD thesis in 2013, I joined the National Cancer Institute (Bethesda, MD) for a postdoctoral fellowship at the Clinical Pharmacology Program headed by Doug Figg, PharmD. As a postdoc, I focused on several translational projects including pharmacogenetic analyses of the HDAC inhibitor belinostat and preclinical drug development of marine sponge compounds as potential anti-angiogenesis agents.
In 2016, I moved back to the Netherlands to start a hospital pharmacy residency program at Erasmus Medical Center in Rotterdam, which I combined with a postdoc position at the Personalized Medicine group of Ron Mathijssen, MD, PhD. From 2016-2019 I focused on pharmacogenetic analyses of anticancer drugs, such as vemurafenib and irinotecan. Being convinced of the value of pharmacogenetics for optimizing anticancer therapy, I look forward to exploring this field further at Roswell Park Comprehensive Cancer Center.
Currently, the response to anticancer therapy is characterized by wide inter-individual variation. My laboratory has a special interest in reducing this variation by individualizing treatment of cancer patients. In addition to the numerous efforts that are currently being made to select the best drugs based on tumor characteristics, our focus is making sure that these drugs are administered at the optimal dose to maximize drug efficacy and minimize toxicity. By performing pharmacogenetic analyses of clinical studies, we hope to identify polymorphisms in drug-metabolizing enzymes and drug transporters that affect the pharmacokinetics (PK) and pharmacodynamics (PD) of anticancer drugs. Ultimately, clinically relevant gene-drug interactions could lead to the development of genotype-directed dosing strategies for anticancer therapies.
- de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S – Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018 Oct;57(10):1229-1254.
- Goey AKL, Chau CH, Sissung TM, Cook KM, Venzon DJ, Castro A, Ransom TR, Henrich CJ, McKee TC, McMahon JB, Grkovic T, Cadelis MM, Copp BR, Gustafson KR, Figg WD - Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction. J Nat Prod. 2016 May 27;79(5):1267-75.
- Goey AKL, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, Ehrlich S, Bryla C, Balasubramaniam S, Piekarz R, Steinberg S, Bates SE, Figg WD - Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics and toxicities of belinostat administered by 48 h continuous infusion in patients with cancer. J Clin Pharmacol. 2016 Apr;56(4):461-73.
- Goey AKL, Beijnen JH, Schellens JHM - Herb-drug interactions in oncology. Clin Pharmacol Ther. 2014 Apr;95(4):354-5.
- Goey AKL, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, Burgers JA, Beijnen JH, Schellens JHM - The effect of St. John’s wort on the pharmacokinetics of docetaxel. Clin Pharmacokinet. 2014 Jan;53(1):103-10.